• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Intron A (Interferon alfa-2b, recombinant)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Intron A (Interferon alfa-2b, recombinant)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Intron A is the first adjuvant therapy to surgery that has been shown to significantly increase relapse-free and overall survival in subjects with malignant melanoma. The product has previously received U.S. marketing clearance for treating hairy cell leukemia, AIDS-related Kaposi's sarcoma, condylomata acuminata, and chronic hepatitis B and C.

    Intron A is an interferon, a group of naturally occurring proteins that were first discovered as a result of their ability to prevent viral replication. Additional research has determined that interferons have anti-tumor effects and are useful in fighting some types of cancer cells. Intron A is marketed in 72 countries worldwide for as many as 16 indications.

    Clinical Results

    In 1985, a large, randomized, controlled phase III clinical trial conducted at 29 centers by the Eastern Cooperative Oncology Group, in conjunction with the National Cancer Institute, 280 malignant melanoma subjects were randomized to either treatment with Intron A or observation post surgery. The primary study objectives were to determine the effectiveness of Intron A in prolonging relapse-free and overall survival. A marked improvement in each of these categories was demonstrated.

    In the clinical study, the addition of Intron A after surgical removal of the tumor increased median overall survival of malignant melanoma subjects by more than 12 months and median relapse-free survival by 9 months. A 24% improvement in the five-year survival rate was demonstrated. A 42% improvement in the five-year relapse-free survival rate was demonstrated for subjects receiving Intron A therapy.

    Side Effects

    Side effects included decreased white blood cell counts, fever, myalgia, anorexia, vomiting/nausea, increased liver enzyme level, headache, chills, and depression. Side effects were expected and controllable through dose modifications.

    Mechanism of Action

    The exact mechanism of action is unknown. Intron A has been shown to have intracellular, antiviral immunomodulatory, and antiproliferative effects, in-vitro and in-vivo. These include effects on intracellular oncogene expression, stimulation of natural killer and cytotoxic T-cells, microphage activation, and induction of cytokine production. Antiproliferative effects shown include slowing of cell division and reversion of tumor cells to a normal phenotype.

    Additional Information

    Malignant melanoma is the deadliest of three main types of skin cancer; the other two are basal cell carcinoma and squamous cell carcinoma. Malignant melanoma causes approximately 7,200 deaths in the United States a year. The incidence of malignant melanoma is rising 4% each year in the United States., with 34,100 new cases expected to be diagnosed in 1995, according to the American Cancer Society.

    Approval Date: 1995-12-01
    Company Name: Schering-Plough
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing